NCT00677872终止2 期
An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Six-minute walk test (6-MWT)and mean pulmonary artery pressure (MPAP) utilizing right heart catheterization.
研究概览
简要总结
A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and Women >40 years of age
- •Diagnosis of COPD with an FEV1 above 20% and less than 65% of predicted normal and an FEV1-to-FVC ratio of less than 70%
- •Diagnosis of pulmonary hypertension based on echocardiography within the last 6 months or by cardiac catheterization within the last 12 months
- •New York Heart Association(NYHA)Class II or III
- •Screening LVEF>55%, obtained by any appropriate method within 6 months of screening
- •Baseline 6MWT distance>150m and <450m
- •Written informed consent from each subject prior to the initiation of any study-related procedure
- •Documented negative results (within 12 months)and Hepatitis B and Hepatitis C Serology
排除标准
- •Treatment for pulmonary hypertension with epoprostenol (prostacyclin), trepostinil (Remodulin), iloprost (Ventavis), bosentan (Tracleer), ambrisentan (Letairis), sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) within the 30 days prior to study entry
- •Presence or history of any of the following cardiovascular co-morbidities or conditions: Un-controlled systemic hypertension at screening; unstable cardiovascular disease including intermittent atrial fibrillation or unstable angina within the 4 weeks prior to screening; amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis; history of myocardial infarction, coronary artery bypass graft surgery, or percutaneous cardiac intervention within the 3 months prior to screening; significant valvular heart disease; cerebrovascular accident or transient ischemic attack within 3 months prior to screening
- •COPD exacerbation less than 1 month prior to screening
- •Exercise tolerance limited by non-cardiac causes
- •Clinically significant psychiatric, addictive, neurologic disease or condition
- •Chronic renal impairment or renal insufficiency
- •No clinically significant laboratory abnormalities
- •Subjects currently being treated for PH with prostnoids, PDE-5 inhibitors and or endothelin receptor antagonist. The use of PDE-5 inhibitors "as needed" for erectile dysfunction is acceptable as long as the subject does not take the medication within 72 hours of an efficacy assessment. Other concomitant medications are allowed provided the subject has been on a stable dose regimen for at least 4 weeks prior to enrollment and the regimen continues and remains stable during the treatment and follow-up periods.
- •History of nasal airway mass, septal perforation, chronic sinusitis, lidocaine allergy or current nasal passage condition that would decrease the safety or tolerability of a naso-esophageal catheter
- •The subject has the presence, or history, of malignancy that required significant medical intervention within the preceding 3 months and/or is likely to result in death within the next 2 years
- •The receipt of any investigational medication within 30 days prior to screening or anytime during the course of the study
- •Women cannot be pregnant or breastfeeding
研究组 & 干预措施
1
Experimental
干预措施: PRX-08066 (Drug)
结局指标
主要结局
Six-minute walk test (6-MWT)and mean pulmonary artery pressure (MPAP) utilizing right heart catheterization.
次要结局
- Central hemodynamic and exercise capacity parameters utilizing RHC and CPET
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseParkinson's DiseaseNCT01096186Impax Laboratories, LLC617
已完成
3 期
Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the KneeOsteoarthritis of the KneeNCT03046446Pacira Pharmaceuticals, Inc208
终止
3 期
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisPsoriasisNCT01163253Pfizer2,867
撤回
3 期
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)Generalized Anxiety DisorderNCT00738738Pfizer
已完成
1 期
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) DiseaseBatten DiseaseNCT05174039Beyond Batten Disease Foundation6